Allelic association of the neuronal nitric oxide synthase (NOS1) gene with schizophrenia

Nitric oxide (NO) has been identified as a widespread and multifunctional biological messenger molecule in the central nervous system (CNS), with possible roles in neurotransmission, neurosecretion, synaptic plasticity, and tissue injury in many neurological disorders, including schizophrenia. Neuronal NO is widely produced in the brain from L-arginine catalyzed by neuronal NO synthase (NOS1). We therefore hypothesized that the NOS1 gene may play a role in the pathophysiology of schizophrenia. In the present study, we examined the genetic association between a novel single nucleotide polymorphism (SNP: a C→T transition located 276 base pairs downstream from the translation termination site) of the human NOS1 gene, which is located in chromosome 12q24, and schizophrenia (215 Japanese patients with schizophrenia and 182 healthy controls). The allele frequencies of the polymorphism in exon 29 of the NOS1 gene differed significantly between patients with schizophrenia and controls (χ2 = 20.10, df = 1, P = 0.000007; relative risk = 1.92; 95% confidence interval = 1.44–2.55). Our results suggest that the NOS1 gene polymorphism may confer increased susceptibility to schizophrenia.

[1]  Ivan Izquierdo,et al.  Retrograde messengers, long-term potentiation and memory , 1995, Brain Research Reviews.

[2]  J. Drazen,et al.  Neuronal NO synthase (NOS1) is a major candidate gene for asthma. , 1999, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[3]  E. Garcia-Rill,et al.  The brain stem reticular formation in schizophrenia , 1991, Psychiatry Research: Neuroimaging.

[4]  T. Dawson,et al.  Nitric oxide in health and disease of the nervous system , 1997, Molecular Psychiatry.

[5]  P. Emson,et al.  Localization of brain nitric oxide synthase (NOS) to human chromosome 12. , 1992, Genomics.

[6]  S. Snyder,et al.  Cloned and expressed macrophage nitric oxide synthase contrasts with the brain enzyme. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[7]  J. Garthwaite,et al.  NMDA receptor activation induces nitric oxide synthesis from arginine in rat brain slices. , 1989, European journal of pharmacology.

[8]  S. Mukherjee,et al.  Free radical pathology and antioxidant defense in schizophrenia: a review , 1996, Schizophrenia Research.

[9]  T. Dawson,et al.  Neurobiology of nitric oxide. , 1996, Critical reviews in neurobiology.

[10]  S. Vincent,et al.  Nitric oxide: A radical neurotransmitter in the central nervous system , 1994, Progress in Neurobiology.

[11]  F. Murad,et al.  Nitric oxide activates guanylate cyclase and increases guanosine 3':5'-cyclic monophosphate levels in various tissue preparations. , 1977, Proceedings of the National Academy of Sciences of the United States of America.

[12]  D. Kammen,et al.  Effects of haloperidol on antioxidant defense system enzymes in schizophrenia. , 1998, Journal of psychiatric research.

[13]  Jeffrey K. Yao,et al.  Reduced level of plasma antioxidant uric acid in schizophrenia , 1998, Psychiatry Research.

[14]  S H Snyder,et al.  Nitric oxide: first in a new class of neurotransmitters. , 1992, Science.

[15]  P. Marsden,et al.  Structural organization of the human neuronal nitric oxide synthase gene (NOS1). , 1994, The Journal of biological chemistry.

[16]  D. Horrobin,et al.  Fatty acid levels in the brains of schizophrenics and normal controls , 1991, Biological Psychiatry.

[17]  E. Kandel,et al.  Tests of the roles of two diffusible substances in long-term potentiation: evidence for nitric oxide as a possible early retrograde messenger. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[18]  S. Mahadik,et al.  Oxidative injury and potential use of antioxidants in schizophrenia. , 1996, Prostaglandins, leukotrienes, and essential fatty acids.

[19]  J. Garthwaite.  Glutamate, nitric oxide and cell-cell signalling in the nervous system , 1991, Trends in Neurosciences.

[20]  T. L. Krukoff.  Central actions of nitric oxide in regulation of autonomic functions , 1999, Brain Research Reviews.

[21]  Cloned and expressed nitric oxide synthase structurally resembles cytochrome P-450 reductase , 1991 .

[22]  S. Vincent,et al.  Neuronal NADPH diaphorase is a nitric oxide synthase. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[23]  J. Cadet,et al.  Free radical mechanisms in schizophrenia and tardive dyskinesia , 1994, Neuroscience & Biobehavioral Reviews.

[24]  J. Gilbert,et al.  SNPing away at complex diseases: analysis of single-nucleotide polymorphisms around APOE in Alzheimer disease. , 2000, American journal of human genetics.

[25]  J. Smythies.  Redox aspects of signaling by catecholamines and their metabolites. , 2000, Antioxidants & redox signaling.

[26]  R. Pioli,et al.  The inflammatory response system in treatment-resistant schizophrenia: increased serum interleukin-6 , 1998, Schizophrenia Research.

[27]  Terry D. Lee,et al.  Cloning and characterization of inducible nitric oxide synthase from mouse macrophages. , 1992, Science.

[28]  R. Reddy,et al.  Free radical pathology in schizophrenia: a review. , 1996, Prostaglandins, leukotrienes, and essential fatty acids.

[29]  S. Mukherjee,et al.  Impaired antioxidant defense at the onset of psychosis , 1996, Schizophrenia Research.

[30]  J. Cunningham,et al.  Molecular cloning and functional expression of an inducible nitric oxide synthase from a murine macrophage cell line. , 1992, The Journal of biological chemistry.

[31]  Yang Wang,et al.  Neuronal NOS: gene structure, mRNA diversity, and functional relevance. , 1999, Critical reviews in neurobiology.

[32]  S. Snyder,et al.  Nitric oxide mediates glutamate-linked enhancement of cGMP levels in the cerebellum. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[33]  J. Smythies.  Oxidative reactions and schizophrenia: A review-discussion , 1997, Schizophrenia Research.

[34]  C A Sandman,et al.  Altered distribution of nicotinamide-adenine dinucleotide phosphate-diaphorase cells in frontal lobe of schizophrenics implies disturbances of cortical development. , 1993, Archives of general psychiatry.

[35]  J J Kim,et al.  Distorted distribution of nicotinamide-adenine dinucleotide phosphate-diaphorase neurons in temporal lobe of schizophrenics implies anomalous cortical development. , 1993, Archives of general psychiatry.

[36]  S. Mukherjee,et al.  Enzymes of the antioxidant defense system in chronic schizophrenic patients , 1991, Biological Psychiatry.

[37]  T. Shinkai,et al.  Manganese Superoxide Dismutase Gene Polymorphism and Schizophrenia: Relation to Tardive Dyskinesia , 2000, Neuropsychopharmacology.

[38]  E. Garcia-Rill,et al.  Mesopontine neurons in schizophrenia , 1995, Neuroscience.

[39]  S. Dursun,et al.  Lack of phencyclidine-induced effects in mice with reduced neuronal nitric oxide synthase , 2001, Psychopharmacology.